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Renal Cell Carcinoma (RCC) is responsible for approximately 13,500 deaths in the US 
each year and 65,000 new cases are diagnosed here annually. Despite the approval of 
multiple new drugs targeting mTOR and angiogenic pathways, there is still no curative 
treatment. Only 20-30% of patients respond to these targeted therapies; all eventually 
become resistant and progress. One of the most widely used targeted therapies is sunitinib, 
a tyrosine kinase inhibitor (TKI) primarily targeting the vascular endothelial growth factor 
receptors (VEGFRs). There is some evidence that sunitinib has off-target effects on the 
immune system, including reducing the number of myeloid derived suppressor cells 
(MDSCs) but also causing lymphopenia in patients. Recently completed and ongoing 
clinical trials of monotherapy with antibody blockade of Programmed Death 1 (PD-1) have 
demonstrated efficacy in RCC patients. We explored the therapeutic potential, as well as 
the immunomodulating effects, of combined sunitinib and anti-PD-1 antibody therapy 
using the orthotopic murine Renca model of RCC. Though short-term experiments did not 
reveal a significant increase in therapeutic potential over sunitinib alone, we did observe 
significantly more IFNγ+ CD8 T cells in the tumor-infiltrating lymphocytes (TIL) of 
combination-treated mice compared to those who received sunitinib alone. We also 
examined the effect of sunitinib therapy on the in vivo expression of B7-H1/PD-L1, a 
known ligand for PD-1, on tumor cells harvested from treated, tumor-bearing mice. In 
wild-type Balb/c mice, sunitinib therapy significantly reduced B7-H1 expression. This 
decrease in B7-H1 expression, as well as the dramatic therapeutic effect of sunitinib, were 
not seen in Balb/c RAG knockout mice, however.  While the combination of sunitinib and 
anti-PD-1 antibody was not effective in our orthotopic Renca model, the rationale behind 
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combining anti-angiogenic therapy, particularly TKIs, with immune checkpoint blockade 
is supported by an extensive body of literature and worthy of continued investigation. 
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The American Cancer Society estimates there will be 61,560 new cases of all types of 
kidney cancers and 14,080 deaths attributable to kidney cancer in the United States alone 
in 2015 (1). In their earliest stages, when the chance for complete cure through surgical 
resection is highest, renal cancers are frequently asymptomatic. Unless diagnosed early due 
to incidental diagnostic scans, many patients present with metastatic disease. While 5 year 
survival rates are now above 70% for patients diagnosed at Stage I or II, survival declines 
to just over 50% for Stage III and drops to less than 10% for those who present with Stage 
IV disease (2). With traditional cytotoxic chemotherapies and radiation providing little or 
no benefit, there has long been a significant unmet need for curative therapies, particularly 
in the setting of advanced and metastatic disease. 
Renal cancers are unique in that they are one of only a handful of naturally “immunogenic” 
cancers, as evidenced by spontaneous regression of metastatic disease following surgical 
resection of the primary tumor (3,4). This immunogenic potential led to the introduction of 
high-dose interleukin-2 (IL-2) therapy more than thirty years ago, followed by interferon-
α (IFN-α). Neither of these cytokines is particularly effective – historically only 5-10% of 
treated patients achieved remission. Even with more recent selection for the most favorable 
histological sub-types, only 25% of patients treated with IL-2 achieve durable responses 
(5). Many patients are unable to tolerate the potentially life-threatening side effects of 




The 2005 approval of sorafenib, an oral kinase inhibitor, marked a turning point for the 
treatment of kidney cancer. Sorafenib and the numerous targeted therapies that have 
followed arose from a better understanding of the underlying genetics and angiogenic 
characteristics of renal malignancies. Clear Cell Renal Cell Carcinoma (RCC) accounts for 
66 – 75% of all kidney cancer cases and many of these cancers have a characteristic genetic 
change in a tumor suppressor gene – the von Hippel-Lindau (VHL) mutation(6). The von 
Hippel-Lindau protein negatively regulates hypoxia inducible factor 1a (HIF1a) through 
ubiquitination and subsequent degradation. Without this regulation, HIF1a induces 
angiogenic genes including vascular endothelial growth factor (VEGF) (7). Sorafenib 
actually targets multiple kinases, including the serine/threonine kinases C-RAF and B-RAF 
as well as the tyrosine kinases of the VEGF receptor (VEGFR) and platelet-derived growth 
receptor (PDGFR) families (8). This dual action may curb tumor growth by inhibiting 
tumor cell proliferation and survival (C-RAF and B-RAF) while simultaneously slowing 
angiogenesis via VEGFR/PDGFR.  
Shortly after sorafenib’s approval, sunitinib, an oral receptor tyrosine kinase inhibitor 
(TKI), received FDA approval in early 2006. Like sorafenib, sunitinib targets the 
VEGFR/PDGFR families but also demonstrates inhibition of KIT, FLT3 and colony-
stimulating factor receptor type 1 (9). Initial response rates are between 30% and 40% but 
complete responses are rare and it is not considered a curative therapy (10–12). Though 
sunitinib, like so many targeted therapies, is administered orally, it is not without side 
effects. Commonly reported side-effects observed in a large, randomized Phase III trial 
comparing sunitinib to IFN-α were nausea, diarrhea, hypertension, fatigue, stomatitis and 
hand-foot syndrome (13). Laboratory abnormalities included increased lipase and uric acid 
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as well as multiple hematologic deficiencies - leukopenia, neutropenia, thrombocytopenia 
and lymphopenia. Cardiotoxicity and hypothyroidism occurred less frequently but at 
significantly higher rates in the sunitinib-treated patients. Trial participants taking sunitinib 
were almost twice as likely as the IFN-α cohort to require a dose reduction (50% vs 27%). 
Dose reductions and interruptions are extremely common among patients taking sunitinib. 
This is unfortunate because sunitinib seems to be most effective at higher concentrations – 
increased sunitinib exposure is associated with a higher probability of a partial or complete 
response as well as lengthier time to progression and overall survival (14). The Phase III 
trial mentioned above also demonstrated increased response rates with longer duration 
sunitinib treatment (15). For the RCC patients who are able to remain on sunitinib therapy, 
many will develop resistance after a median 6-15 months of treatment (16). There are likely 
to be several factors contributing to this resistance, including alternate proangiogenic 
pathways that ultimately lead to the revascularization of the tumor and various factors in 
the tumor microenvironment (TME) and stroma, such as cytokines and 
immunosuppressive cells (16,17). The emergence of resistance has led to patients being 
treated sequentially with multiple targeted therapies, though simultaneous combinations 
have also been explored. Several of these combinations have demonstrated significant 
toxicities with little gain in efficacy (18). 
Given the promiscuity of kinase inhibitors, it is not surprising that their use is associated 
with off-target effects, particularly of the immunologic variety. Sorafenib seems to 
interfere with immune activation by inhibiting dendritic cell functionality on multiple 
fronts, but sunitinib does not and may actually reduce the numbers of regulatory T cells 
(19). Sunitinib has also been shown to reduce myeloid derived suppressor cell (MDSC) 
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populations in mice bearing Renca tumors (20), as well as in metastatic RCC (mRCC) 
patients (21), and reverse suppression of IFNγ-producing T cells (22).  
As numerous targeted therapies were being tested in clinical trials, there was a similar surge 
in cancer immunotherapy agents, particularly for immunogenic malignancies such as 
melanoma and RCC. Immunotherapy is especially attractive because it has the potential to 
induce a memory response through the adaptive immune system, something targeted 
therapies cannot offer. Tumors employ numerous strategies to evade destruction by the 
host immune system, which translate to multiple therapeutic opportunities to overcome 
these barriers (23). At the forefront of the possible immunotherapeutic approaches is 
immune checkpoint blockade (24,25). Our immune systems depend on a delicate balance 
between co-stimulatory and checkpoint molecules to control our immune responses, 
keeping pathogens at bay while simultaneously preventing autoimmunity. This exquisite 
control occurs largely through the various checkpoint molecules and their ligands which 
can modulate the amplitude, duration and breadth of T and B cell responses. 
 
The most widely studied of these checkpoint molecules include cytotoxic T lymphocyte 
antigen 4 (CTLA-4) and programmed death 1 (PD-1) along with its ligand PD-L1 (also 
called B7-H1).  Ipilimumab, which blocks CTLA-4, was brought to market first, garnering 
FDA approval for unresectable metastatic melanoma in 2011 based on its improved overall 
survival in a randomized phase III trial (26). In a phase II trial in mRCC patients, 
ipilimumab demonstrated a response rate of 13% but 33% of patients experienced a grade 
III or IV immune-related adverse event (IRAE) (27). This high rate of IRAEs is not 
surprising given CTLA-4’s expression profile and the phenotype of CTLA-4 knockout 
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mice, which develop lymphoproliferative disease leading to tissue destruction and death at 
only 3-4 weeks of age (28). PD-1 and PD-L1 targeted antibodies have a better safety profile 
than those blocking CTLA-4, with substantially fewer IRAEs. PD-1 and PD-L1 are 
primarily active in the tumor microenvironment rather than the lymph nodes, leading to 
more tumor-targeted immune activation rather than the systemic activation seen with 
CTLA-4 blockade. Even PD-1 knockout mice fare better than those lacking CTLA-4 – 
though not completely without an autoimmune phenotype, these mice tend to develop 
tissue-specific, rather than systemic, responses and live substantially longer (29,30).   
  
In light of the history of immunotherapy in mRCC, there was much interest in developing 
new treatments that took advantage of our vastly expanded knowledge of the immune 
system and its interaction with the TME. Numerous different vaccine strategies continue 
to be explored (31) but previous links between tumoral B7-H1 expression and poor 
prognosis in RCC patients pointed to the potential of targeting the PD-1-PD-L1 interaction 
(32–38). Frigola et al found a soluble form of B7-H1 in the sera of RCC patients that was 
associated with larger tumors, advanced stage and grade as well as a higher risk of death 
(39). With an intact binding domain, this soluble B7-H1 is still capable of delivering pro-
apoptotic signals to T cells. Additionally, PD-1 expression was seen on tumor-infiltrating 
immune cells of mRCC patients and was associated with larger tumors of a higher grade 
and an increased risk of cancer-specific death (40). The frequently observed expression of 
both tumor cell B7-H1 and immune cell PD-1 makes the PD-1-PD-L1 axis a logical target 
in mRCC, offering the potential for significant tumor regression without the serious 
immunological side effects seen with ipilimumab. 
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Multiple antibodies targeting PD-1 and PD-L1 were explored as monotherapies in mRCC 
patients. The first anti-PD-L1 antibody tested, BMS 936559, had an excellent safety profile 
but the objective response rate in mRCC was a disappointing 12% (41), prompting Bristol 
Myers to abandon it and focus their efforts on their simultaneously tested anti-PD-1 
antibody, BMS 936558, now known as nivolumab. Nivolumab was tested for safety, 
tolerability and efficacy in Phase I and II trials. It has demonstrated efficacy in mRCC 
patients with objective response rates ranging from 17% to 29% and significantly fewer 
grade III or IV IRAEs than seen with ipilimumab (42–46). Genentech’s MPDL3280A also 
targets PD-L1 and proved to be well-tolerated with no dose-limiting toxicities, pneumonitis, 
colitis or deaths attributed to treatment (47). Though the response rate was similar to BMS 
936559, there are ongoing clinical trials of MPDL3280A in mRCC.  
With sunitinib already approved for mRCC and such promising responses in phase I and 
II trials of nivolumab monotherapy with manageable IRAEs, we wondered if there would 
be a synergistic therapeutic effect between the two. We chose to use the orthotopic Renca 
murine model of RCC for our studies, believing it to be more physiologically relevant than 
the more frequently employed subcutaneous model. Renca is among the “highly 
immunogenic” murine models, based on immunoprofiling, slow tumor growth in vivo and 
response to an immunotherapy regimen (which did not involve checkpoint blockade) (48). 
The highly immunogenic tumors identified in this study were also marked by large 
numbers of suppressor cells but very few infiltrating cytotoxic T cells. These observations 
suggest that an approach that reduces suppressor cell populations while increasing tumor 
vasculature permeability and simultaneously enhancing the activity and number of tumor-
specific T cells would be most effective in a highly immunogenic tumor such as Renca. 
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Based on the literature, the combination of sunitinib and anti-PD-1 antibody should provide 




MATERIALS AND METHODS 
Cell Lines: Renca cells were purchased from ATCC (catalog # CRL-2947) and grown in 
RPMI supplemented with 10% heat-inactivated fetal bovine serum, Non-Essential Amino 
Acids (0.1 mM), Sodium Pyruvate (1 mM), L-glutamine (2 mM) and 
penicillin/streptomycin. Mycoplasma testing of cultured cells was conducted with R&D 
Systems’ MycoProbe Mycoplasma Detection Kit according to the kit directions. 
Mice: Female BALB/cJ mice (8-10 weeks of age) were ordered from The Jackson 
Laboratory (stock number 000651). Female BALB/c RAG-/- mice (8-10 weeks of age) were 
originally a generous gift from Hyam Levitsky but were later maintained and bred by our 
laboratory. Mice were housed in specific-pathogen-free facilities. All experimental 
procedures were performed in accordance with protocols approved by the Johns Hopkins 
University Institutional Animal Care and Use Committee. 
Tumors: For orthotopic tumors, cells were harvested with Trypsin-EDTA (0.25%) which 
was neutralized with complete medium, spun down @ 800 RPM then washed twice in 
RPMI alone. After counting, the cells were resuspended in 50% RPMI/50% Matrigel (BD 
Biosciences) at the appropriate concentration. Mice were anesthetized with a Ketamine 
(100 mg/kg)/Xylazine (20 mg/kg) combination via intraperitoneal injection. Once adequate 
depth of anesthesia was confirmed, the pre-shaved area of the right flank was cleansed with 
an isopropanol wipe and a 2 cm incision was made through the skin. A slightly smaller 
incision was made in the peritoneum and the kidney was gently brought out of the 
abdominal cavity. An 18 gauge needle was inserted into the bottom of the kidney and 
pushed up through the cortex of the kidney then carefully removed. Using a 50 µl glass 
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Hamilton syringe with a 26 gauge 5/8 inch blunt needle, 30 µl of cell suspension was 
injected into the kidney capsule at the top of the kidney. After withdrawing the needle, the 
kidney was returned to the abdominal cavity and the peritoneum was closed with 1-2 
stitches. The skin incision was then closed with three 9 mm surgical clips and triple 
antibiotic ointment was applied. Mice received 5 mg/kg Ketoprofen intraperitoneally and 
were kept warm while recovering from anesthesia. For subcutaneous tumors, cells were 
harvested with Trypsin-EDTA (0.25%) which was then neutralized with complete medium, 
spun down @ 800 RPM then washed twice in RPMI alone. After counting, the cells were 
resuspended in RPMI alone at the appropriate concentration. Tumors were established by 
subcutaneous injection of 50 µl of cell suspension in the mouse’s flank. Tumors were 
measured 2-3 times weekly using digital calipers and tumor volume was calculated using 
the modified ellipsoid formula of 1/2 (Length x Width2) (49,50). Tumor-bearing mice were 
sacrificed when tumor volume exceeded 1500 mm3 or tumors became ulcerated. 
Sunitinib: For in vitro experiments, Free Base Sunitinib/Sutent/SU-11248 (S-8877) was 
purchased from LC Laboratories and dissolved in DMSO to yield a 5mM stock solution. 
All in vivo experiments utilized Sunitinib Malate Salt/Sutent/SU-11248 (S-8803, LC 
Laboratories) which was resuspended in Ora-Plus (Paddock Laboratories) at a 
concentration of 10.4 mg/ml. Unless otherwise specified, mice were dosed daily with 40 
mg/kg via oral gavage, a dose recommended by our colleague Hans Hammers to most 
closely model the effect of sunitinib in renal cell carcinoma patients but not completely 
eradicate or prevent the growth of tumors in mice. 
Anti-PD-1 Antibodies: Anti-PD-1 antibody was purified from a hamster monoclonal 
antibody (mAb)-producing hybridoma (clone G4, a gift from Leiping Chen) supernatant 
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produced in our laboratory for the earliest experiments and later provided by CoStim 
Pharmaceuticals (clone 8H3). Mice not receiving anti-PD-1 antibody were given the 
appropriate isotype-matched control. Antibodies and isotype controls were dosed 3 times 
at 10 mg/kg in sterile PBS, administered every 3 days via intraperitoneal injection. 
Cell/Tissue Harvest: Mice were first anesthetized with a Ketamine (150 mg/kg)/Xylazine 
(30 mg/kg) combination via intraperitoneal injection. Once an extremely deep state of 
anesthesia was confirmed, mice were perfused with 30 ml of 1x PBS via transcardial 
perfusion using a 21 G Vacutainer Safety-Lok Blood Collection Set (BD) inserted into the 
left ventricle and then severing the inferior vena cava. Spleens, lymph nodes, normal 
kidneys and tumors/tumor-bearing kidneys were all harvested into harvest media. A single 
cell splenocyte suspension was generated by mashing spleens through a 100 micron cell 
strainer which was rinsed with harvest media, then centrifuging at 1200 rpm for 5-7 
minutes, decanting and resuspending in 2.5 ml ACK Lysing Buffer for 2 minutes before 
dilution with 1x PBS. They were again spun down, decanted and the resulting cell pellets 
were resuspended in 10 ml harvest media for counting and eventual staining or plating for 
stimulation. Lymph nodes were mashed in a 24 well dish, then transferred to a 
microcentrifuge tube for pelleting at 1200 rpm for 5 minutes in a benchtop centrifuge then 
resuspending in 500 µl – 1 ml of harvest media (depending on the size of the pellet). 
Kidneys and tumor-bearing kidneys were typically weighed and photographed prior to 
processing. For isolating infiltrating lymphocytes, kidneys and tumors/tumor-bearing 
kidneys were coarsely chopped with scissors, mashed through a 100 micron cell strainer, 
washed, pelleted and then subjected to a 44%/67% Percoll (GE Healthcare, 17-0891-01) 
gradient. The buffy coat was removed, washed, pelleted and resuspended in harvest media 
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for counting and eventual plating for staining or stimulation. When the kidney or tumor 
cells themselves were desired for analysis, non-necrotic tissue was selected and finely 
minced with razor blades before digestion in a shaker for 2 hours at 37ᵒC in Collagenase I 
(1 mg/ml, Life Technologies, 17100-017). Following digestion, the samples were pelleted, 
decanted and resuspended in 3 ml warm Trypsin-EDTA (0.25%) followed by a 5 minute 
incubation at 37ᵒC. The Trypsin was neutralized with 3 ml harvest media containing 500 
U DNase I (Roche, 10104159001) before filtering the samples through a 70 micron cell 
strainer. After pelleting and decanting, the digested cells were resuspended in media to be 
plated for surface staining for flow cytometry. 
Flow Cytometry/Intracellular Cytokine Staining: Before staining, samples intended for 
intracellular cytokine analysis were stimulated for 5-6 hours in harvest media 
supplemented with phorbol 12-myristate 13-acetate (PMA, 5 ng/ml), Ionomycin (500 
ng/ml) and Protein Transport Inhibitor Cocktail (1:500, eBioscience). For experiments with 
more than four colors, cells were first incubated with LIVE/DEAD Fixable Aqua 
(Invitrogen) diluted 1:5000 in 1x PBS for 30 minutes at room temperature in the dark, then 
washed with 1x PBS or FACS buffer (1x PBS and 5% FBS). Flow antibodies (purchased 
from BD Pharmingen, eBiosciences, Biolegend or Invitrogen) were diluted in PBS or 
FACS buffer for surface staining or Permeabilization Buffer (eBioscience, 00-8333-56) for 
intracellular staining. For surface staining, cells were incubated in the diluted antibody 
cocktails for 20-30 minutes at room temperature in the dark, then washed with 1x PBS or 
FACS buffer. If no intracellular staining was to be performed, the samples were either 
resuspended in PBS or FACS buffer for immediate analysis or subjected to a gentle 30 min 
fixation in 2% paraformaldehyde at 4ᵒC for later analysis. For intracellular staining, cells 
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were incubated in Fixation/Permeabilization solution (eBioscience, 88-8824-00) for 45 
minutes at room temperature in the dark, then washed with Permeabilization Buffer before 
incubation in the intracellular antibody cocktail for 20-30 minutes at room temperature in 
the dark. After staining, the cells were washed with Permeabilization Buffer and 
resuspended in PBS. Samples were analyzed using either a FACSCalibur (BD) or LSR II 
(BD) and flow cytometric data were exported and analyzed using FlowJo software (Tree 
Star, Inc.). Graphing and statistical analyses (unpaired, two-tailed Student’s t-test) were 





Combination therapy in orthotopic tumors from Mycoplasma-contaminated cell 
cultures Preliminary in vivo experiments in our laboratory examined the anti-tumor and 
immunologic effects of sunitinib and anti-PD-1 antibody alone or combined in a small 
number of mice orthotopically implanted with 5 x 105 Renca cells. After five days of tumor 
growth, anti-PD-1 antibody was administered every three days for a total of five doses. 
Sunitinib treatment was started after eight days and continued daily through the end of the 
experiment (day 20).  While the combination therapy showed only a modest increase in 
anti-tumor effect compared to sunitinib alone (Figure 1A),  the numbers of IFNγ+ CD8 T 
cells and IL-2+ CD4 T cells in the tumor draining lymph nodes (TDLN) increased 
dramatically (49-fold and 14-fold respectively) (Figure 1B-C). 
Unfortunately, routine testing of the Renca cells used in these early experiments revealed 
that the frozen stocks were all contaminated with Mycoplasma bacteria. Newly purchased 
Renca cells from ATCC were expanded to make new frozen stocks for future experiments. 
These stocks were Mycoplasma-negative in all subsequent tests. 
 
Combination therapy in orthotopic tumors from Mycoplasma-negative cell cultures 
Multiple in vivo experiments using the same number of implanted cells with the same 
treatment regimen were conducted with these new, uncontaminated Renca cells. No 
individual experiment demonstrated a difference in anti-tumor effect between sunitinib 
alone and combination therapy. Combined tumor burden data from four orthotopic 
experiments (5-10 mice per treatment group in each experiment) clearly illustrates that 
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adding anti-PD-1 antibody to sunitinib does not reduce the tumor burden compared to 
sunitinib treatment alone (p=0.8184) (Figure 2) though both regimens are significantly 
better (p<0.0001) than no treatment or anti-PD-1 alone. Somewhat surprisingly, we found 
that anti-PD-1 monotherapy was no more effective than vehicle/IgG control (p=0.6533). 
On more than one occasion, the mice who received anti-PD-1 antibody alone actually fared 
slightly worse than their untreated counterparts (data not shown), though not to the extent 
shown in Figure 1. 
Flow cytometric analysis of the IFNγ+ CD8 T cells from these experiments did not yield 
the same dramatic differences as the earlier studies with contaminated tumor cultures. The 
following p values and graphs are from a single experiment but are representative of all 
results. In the TDLN, mice receiving combination therapy did not have significantly greater 
numbers (p=0.6467) or percentages (p=0.0635) of IFNγ+ CD8 T cells when compared to 
mice treated with sunitinib alone (Figure 3A-B). There was, however, a difference in the 
numbers of IFNγ+ CD8 T cells in the tumor-infiltrating lymphocytes (TIL) of combination-
treated mice compared to sunitinib alone (p=0.0363) (Figure 3C). Even when tumor 
burden is taken into account, the  number of IFNγ+ CD8 T cells per gram of tumor was 
still significantly different between the two groups (p=0.0347) (Figure 3D). The difference 
in percentage of IFNγ+ CD8 T cells in the TIL was not statistically significant (p=0.2704) 
(Figure 3E). 
We saw none of the differences in IL-2+ CD4 T cells that were observed with the 
Mycoplasma-contaminated Renca cells. In the TDLN, the number of these cells was 
roughly equivalent for all four groups of mice (Figure 4A). When we examined the 
percentage of IL-2+ CD4s, mice receiving the combination treatment did have a 
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significantly greater proportion than the mice who received anti-PD-1 alone (p=0.0379) 
but not those given sunitinib alone (p=0.1412) (Figure 4B). In the TIL, the only significant 
difference was between the numbers of IL-2+ CD4s in the anti-PD-1 only and combination 
mice. Unlike the percentage in the TDLN, here the anti-PD-1 treated mice had significantly 
greater (p=0.0212) numbers of IL-2+ cells (Figure 4C) but a slightly smaller percentage 
(Figure 4E). When tumor weight was taken into consideration, there were no significant 
differences between any of the treatment groups. 
We then looked at a population of CD4 T cells that could potentially be involved in down-
regulating the anti-tumor immune response. FoxP3+ CD4 T cells can be “regulatory” T 
cells and suppress T helper functions during an immune response or play a role in the 
maintenance of tolerance. FoxP3 can also serve as an activation marker though, so without 
a functional suppression assay we cannot say with certainty that the FoxP3+ cells we 
observed were responsible for, or capable of, suppressing the anti-tumor immune response. 
The issue of the validity of FoxP3 as a marker of regulatory T cells is irrelevant in this case 
because there were no significant differences in the numbers or percentages of FoxP3+ 
CD4 T cells in the TDLN or TIL between the sunitinib alone and combination treated mice. 
Mice who received anti-PD-1 plus sunitinib did have somewhat lower numbers of FoxP3+ 
cells in their TDLN (Figure 5A) but the percentages were essentially the same for all of 
the regimens (Figure 5B). In the TIL, the only statistically significant difference we noted 
was between the percentage of FoxP3+ cells of untreated and combination mice (Figure 




Sunitinib treatment has been shown) to decrease the population of myeloid-derived 
suppressor cells (MDSC) in mouse models as well as in RCC patients (51). We observed 
the same phenomenon in our orthotopic Renca experiments, with MDSC defined as GR1+ 
CD11b+ cells by flow cytometric analysis. When examining the TIL, mice treated with 
sunitinib alone or in combination with anti-PD-1 have significantly lower percentages of 
MDSC (p = 0.0001 and p = 0.0003, respectively) when compared to untreated mice (Figure 
6A). For mice treated with anti-PD-1 alone, there is a marked, but not statistically 
significant (p=0.0540), reduction relative to the untreated mice. The same holds true for 
the number of MDSC in the TIL (p=0.0323 for sunitinib, p=0.0294 for combination and 
p=0.4346 for PD-1 alone) (Figure 6B) and per gram of tumor (p=0.0248, p=0.0412 and 
p=0.3135 respectively) (Figure 6C). Though present, the differences were not as 
significant for the number of MDSC in the TDLN (p=0.0569, p=0.0953 and p=0.8311 
respectively) (Figure 6D). 
 
In vitro surface expression of B7-H1, MHC II and B7-DC in Renca cells 
In order to better understand the lack of additional anti-tumor effect conferred by adding 
anti-PD-1 antibody to sunitinib treatment, we examined Renca cells’ in vitro expression of 
three common co-stimulatory molecules – B7-H1 (PD-L1), MHC Class II (the ligand of 
another checkpoint molecule with therapeutic potential, lymphocyte activation gene 3 
(LAG-3)) and B7-DC (PD-L2, another ligand of PD-1) via flow cytometry under different 
culture conditions. At baseline (standard culture media), only B7-H1 expression was 
detected (Figure 7A). In order to simulate how expression might change in the setting of 
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an in vivo anti-tumor immune response, we cultured Renca cells with 100 units/mL 
(10ng/mL) IFNγ. After 24 hours in the presence of IFNγ, B7-H1 expression increased more 
than five-fold from baseline. Median fluorescence intensity (MFI) was 68 at baseline 
compared to 365 when cultured with IFNγ (Figure 7B). MHC II expression was also 
affected - MFI increased from 4.3 to 39 in the presence of IFNγ. B7-DC expression was 
not induced by IFNγ (Figure 7C).  
We then interrogated the direct effect of sunitinib on B7-H1 expression in Renca cells 
cultured with IFNγ. Assuming that 100nM represents a physiologically relevant dose, we 
examined doses of sunitinib ranging from 10nM to 1µM for either 24 or 48 hours but saw 
no effect on the MFI (data not shown) or the percentage of B7-H1 positive cells (Figure 
7D).  
 
In vivo surface expression of B7-H1 and MHC II in harvested tumor cells 
Though sunitinib did not change B7-H1 expression in vitro, we wondered if treatment with 
sunitinib would affect in vivo expression. Orthotopic Renca tumors were implanted in wild-
type (WT) BALB/c mice and allowed to grow for five days before treatment was initiated. 
Mice received vehicle or sunitinib (20 mg/kg) via oral gavage for seven days. Note that 
this sunitinib dose is half our normal dose. It was necessary to use a less effective dose in 
order to yield sufficient tumor tissue for analysis. The tumors were harvested and digested 
to yield a single cell suspension suitable for fluorescent antibody staining and flow 
cytometric analysis. Mice treated with sunitinib had significantly lower percentages of B7-
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H1 positive cells (p=0.0006) (Figure 8A). While not as dramatic a decrease, treated mice 
had significantly reduced proportions of MHC II+ cells (p=0.0116) (Figure 8B). 
 
Sunitinib effects in RAG1-/- tumor-bearing mice 
As a first step towards elucidating the mechanism by which sunitinib was able to reduce 
the proportion of B7-H1 positive tumor cells, we turned to the RAG1-/- mouse model (RAG 
KO) on a Balb/c background. RAG KO mice are unable to perform V(D)J recombination 
and lack mature T and B cells (52). Renca tumors were orthotopically implanted and 
sunitinib or vehicle was administered via oral gavage for nine days, from Day 7 until Day 
15.  Tumors were harvested, weighed and digested to facilitate fluorescent antibody 
staining and flow cytometric analysis. Unlike in WT mice, sunitinib treatment of tumor-
bearing RAG KO mice did not result in a significant reduction in tumor burden (p=0.2888) 
(Figure 9A). Examination of B7-H1 expression via flow cytometry showed that RAG KO 
mice did not exhibit the significant reduction in percentage of B7-H1 positive cells seen in 
WT mice (p=0.0952 vs 0.0006 for WT) (Figure 9B). For MHC II, there was a significant 
reduction with sunitinib treatment in RAG KO mice (p=0.0118), just as in WT mice 
(Figure 9C). Though we do not have B7-DC data for WT mice, in RAG KO mice there 



















Figure 1: Sunitinib + anti-PD-1 combination treatment of Mycoplasma contaminated 
Renca tumors. Sunitinib + anti-PD-1 combination therapy shows a modest increase in 
anti-tumor effect but significantly improves the immunological response to Mycoplasma 
contaminated Renca tumors. Renca cells that were later determined to be contaminated 
with Mycoplasma were orthotopically implanted and, once established, treated with 
Sunitinib, anti-PD-1 monoclonal antibody or a combination of the two. (A) Tumor burden 
of mice in the four treatment groups. 
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(B) Number of IFNγ+ CD8 T cells in the tumor draining lymph nodes. (C) Number of IL-


















Figure 2: Sunitinib + anti-PD-1 combination treatment of Mycoplasma-negative 
Renca tumors. The combination of sunitinib and anti-PD-1 does not increase anti-tumor 
effect compared to sunitinib alone in non-Mycoplasma-contaminated orthotopic Renca 


















































Figure 3: IFNγ+ CD8 T cells in mice treated with combination therapy. IFNγ+ CD8 T 
cells are increased in the TIL, but not TDLN with combination therapy. (A) Number of 















































































































(C) Number of IFNγ+ CD8 T cells in the TIL. (D) Number of IFNγ+ CD8 T cells in the 






































































































































Figure 4: IL-2+ CD4 T cells in mice treated with combination therapy. Mice treated 
with combination therapy do not have significantly greater numbers or percentages of IL-
2+ CD4 T cells in their TDLN or TIL compared to sunitinib treated mice. (A) Number of 


















































































































(C) Number of IL-2+ CD4 T cells in the TIL. (D) Number of IL-2+ CD4 T cells in the TIL 











































































































































Figure 5: FoxP3+ CD4 T cells in mice treated with combination therapy. The number 
and percentages of FoxP3+ CD4 T cells in the TDLN and TIL of combination and 
sunitinib-treated mice were not significantly different. (A) Number of FoxP3+ CD4 T cells 
















































































































(C) Number of FoxP3+ CD4 T cells in the TIL. (D) Number of FoxP3+ CD4 T cells in the 
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Figure 6: Sunitinib and myeloid derived suppressor cells (MDSC). Treatment with 
sunitinib, alone or in combination with anti-PD-1 antibody, reduces myeloid derived 
suppressor cells (MDSC) numbers and percentages. (A) Mice treated with sunitinib alone 
or sunitinib in combination with anti-PD-1 antibody have significantly lower percentages 
and (B) numbers of MDSC in their TIL compared to untreated or anti-PD-1 only mice, as 
well as (C) significantly fewer MDSC per gram of tumor. (D) In the TDLN of mice treated 
with sunitinib alone or the combination therapy, the numbers of MDSC are reduced for 
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Figure 7: In vitro expression of co-stimulatory molecules on Renca cells. Renca cells 
were cultured with and without IFNγ (A) B7-H1 was expressed at baseline and increased 
more than five-fold when cultured with IFNγ. (B) MHC II was not expressed at baseline 
but did respond to IFNγ stimulation. (C) No B7-DC expression was observed at baseline 
or with IFNγ. 
30 
 




























Figure 8: In vivo sunitinib treatment and co-stimulatory molecules. In vivo sunitinib 
treatment reduces B7-H1 and MHC II positivity in harvested tumor cells. Renca tumors 
were implanted orthotopically and allowed to grow for 5 days before commencing 
treatment. Mice received vehicle (No Tx) or 20 mg/kg sunitinib via oral gavage for 7 days 
before tumors were harvested. (A) A significantly lower proportion of tumor cells were 
B7-H1+ in mice treated with sunitinib. (B) The percentage of MHC II+ cells was also 















































































Figure 9: Effects of sunitinib treatment in T and B cell deficient RAG knockout mice. 
The effects of sunitinib were blunted in RAG KO mice. RAG KO mice with established 
orthotopic Renca tumors were given vehicle or sunitinib via oral gavage. (A) After nine 
days of treatment, there was no significant difference in tumor weights between mice who 

















































(B) Percentage of B7-H1+ tumor cells in untreated or sunitinib-treated RAG KO mice. (C) 
A significantly lower proportion of tumor cells were MHC II+ in RAG KO mice treated 





















































































Despite the observed efficacy of anti-PD-1 monotherapy in a subset of renal cell carcinoma 
patients, we found that monotherapy antibody blockade of PD-1 does not reduce tumor 
burden in the orthotopic Renca murine model. As expected, sunitinib monotherapy has 
significant anti-tumor effects in this model. Though it provided a significant therapeutic 
benefit similar to that seen with sunitinib alone, the combination of sunitinib and PD-1 
blockade offered no treatment advantage, at least in the short-term.  While pilot 
experiments showed a dramatic immunological advantage to combination therapy, these 
results were only seen when Mycoplasma-contaminated tumor cell cultures were used to 
establish the orthotopic tumors. The increased numbers of IFNγ+ CD8 T cells and IL-2+ 
CD4 T cells observed in the TDLN of mice given combination therapy could not be 
replicated with Mycoplasma-negative cells.  
In the tumor itself, combination therapy does seem to provide some modest immunological 
benefit over treatment with sunitinib alone. We observed increased numbers of IFNγ+ CD8 
T cells in the TIL of mice given both agents. Despite seeing no short-term therapeutic 
advantage to the combination of sunitinib and anti-PD-1, it may be that in the longer term 
or combined with other immunotherapies, co-administration could prove to be 
advantageous. Sunitinib is known to induce leukopenia and in some of our experiments, 
the combined therapy resulted in greater overall numbers of total cells and of CD4 and 
CD8 T cells specifically in the spleens and lymph nodes (data not shown). This boosting 




Though Renca has been classified as “immunogenic”, the authors of this paper are 
describing the immune infiltrates in subcutaneous Renca tumors and an anti-tumor 
response to their own combinatorial immunotherapy regimen which includes a dendritic 
cell (DC) vaccine and toll-like receptor agonist, not checkpoint blockade (48). It is also 
important to note that the immunosuppression in orthotopic Renca tumors seems to be 
distinct from that seen in subcutaneous tumors, namely that Treg depletion was followed 
by tumor regression in subcutaneous, but not orthotopic, tumors (53). Perhaps an 
immunological “boost” is required for checkpoint blockade to achieve its full therapeutic 
potential in the orthotopic Renca model. The observation that combination therapy makes 
such an enormous difference in the setting of Mycoplasma-contaminated tumor cells 
speaks to the potential for renal cell carcinoma therapeutic vaccines in concert with 
checkpoint blockade and a TKI or other VEGF-targeted therapy. A study utilizing 
irradiated Renca cells as a vaccine showed that while an antitumor memory response was 
generated with the vaccine alone, it was only with the addition of PD-L1 blockade and 
CD4 depletion (targeting Tregs) that tumor regression and long-term protective immunity 
were observed (54). Multiple trials are underway to test RCC vaccines in combination with 
targeted therapies, including sunitinib. The timing of vaccine administration in relation to 
sunitinib therapy can have a significant effect on efficacy however, due to potential 
depletion of CD11b+ CD11c+ antigen presenting cells (55). Historically, vaccines 
targeting mRCC have failed to produce the desired results and none of them have been 
brought to market (56). The past few years have seen a new crop of promising candidates 
but to date no clear winner has emerged (31).  
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One of these is IMA901 which employs 9 tumor-associated peptides (TUMAPS) identified 
through analysis of the mRNA and HLA ligands of 32 RCC patients (57–59). The peptides 
are given intradermally with GM-CSF as an adjuvant and a single low-dose 
cyclophosphamide infusion prior to the first vaccination.  IMA901 has completed Phase I 
and II trials; there is an ongoing Phase III randomized trial in combination with sunitinib 
(NCT01265901).  Also in a randomized Phase III trial with sunitinib is AGS-003, an 
autologous DC vaccine. This approach requires isolating RNA from patient tissue obtained 
during resection and amplifying the RNA for electroporation (along with synthetic CD40L 
RNA) into activated monocyte-derived DCs for infusion. Like other autologous vaccines, 
it is time consuming and very expensive. An open label Phase II trial explored AGS-003 
in combination with sunitinib in treatment-naïve intermediate and poor risk patients. Out 
of 21 patients only 9 experienced partial responses and there were no complete responses 
(60). A randomized Phase III trial comparing AGS-003 plus sunitinib to sunitinib alone as 
a first-line therapy is currently enrolling (NCT01582672). 
A novel approach to therapeutic cancer vaccines involves allogeneic tumor cells modified 
to express the murine α(1,3)galactosyltransferase epitopes (αGal) which induce a robust 
xenoantigen response (61). HyperAcute Renal (HAR) seeks to exploit humans’ pre-
existing antibodies that bind these epitopes, leading to opsonization, complement 
activation and cell lysis. Antigen presenting cells will be recruited for antigen uptake and 
processing which should lead to activation and proliferation of CD4 and CD8 T cells. 
Vaccines for pancreatic, lung, breast and prostate cancer as well as melanoma are currently 
in development. Results to date look promising and Phase II and III trials, including in 
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combination with checkpoint blockade or approved chemotherapy regimens, are already 
underway for some of these indications. 
Our observations concerning the decreased B7-H1/PD-L1 expression seen on tumor cells 
of sunitinib treated mice as well as the blunted effect of sunitinib in RAG KO mice are 
both noteworthy and merit further investigation. The results in RAG KO mice speak to the 
role the immune system plays in sunitinib’s therapeutic effect as well as in the expression 
of B7-H1 and its response to sunitinib. The full extent and mechanism(s) of sunitinib’s 
immunological effects has yet to be completely elucidated. As mentioned earlier, tumor 
PD-L1 expression has historically been associated with poor prognosis in RCC patients. A 
recent large, randomized phase III trial (COMPARZ) comparing sunitinib to pazopanib, 
another VEGF-targeted TKI, as a first-line therapy in patients with mRCC provided further 
evidence of this (62). Both agents demonstrated comparable efficacy, albeit with different 
safety profiles and quality-of-life indicators. Pre-treatment biopsies showed a significant 
negative correlation between tumoral PD-L1 expression and overall survival. The 
differences in overall survival were even more dramatic for patients with high PD-L1 
expression and large numbers of intra-tumoral CD8 T cells. Patients with these findings 
upon initial biopsy may derive benefit from combining PD-1 or PD-L1 blockade with 
VEGF-targeted therapy.  
Expression of PD-L1 post-TKI therapy has not been explored as extensively. A recent 
study reported that mRCC patients who received anti-angiogenic therapy before resection 
of their primary tumor had more infiltrating CD4 and CD8 T cells, which was inversely 
correlated with progression-free survival as well as overall survival (63). These samples 
also had increased CD4+ FoxP3+ regulatory T cells and higher expression of PD-L1, both 
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of which were associated with decreased patient survival. A more informative approach 
would involve examination of paired pre- and post-treatment biopsies. Sharpe et al used 
sequential primary tumor tissue samples from patients enrolled in three phase II trials 
looking at the effects of VEGF-targeted TKI therapy before resection (64). Patients in two 
of the trials received sunitinib while those on the third trial were treated with pazopanib. 
After 12-16 weeks of therapy, PD-L1 expression and the percentage of FoxP3+ cells both 
declined significantly.  No significant differences were observed for these two biomarkers 
between patients who had early or delayed progression or no progression. 
Ongoing studies continue to explore the potential of checkpoint blockade in RCC patients. 
In a clinical trial of ipilimumab and nivolumab as single agents or in combination, the 
combination showed an increased overall response rate with manageable toxicities (65). A 
phase II study is planned to test the same combination against sunitinib monotherapy (NCT 
02231749). A phase Ib trial combining sunitinib and nivolumab found an unacceptably 
high rate of grade 3/4 adverse events (AEs) (73% of patients), leading to over one fourth 
of the participants discontinuing due to AEs (66). This was particularly disappointing given 
that the objective response rate was 52% with median progression-free survival of 48.9 
weeks. After promising clinical activity in a phase Ib trial (67), an ongoing randomized 
phase II study is comparing Genentech’s MPDL 328A anti-PD-L1 antibody alone or in 
combination with bevacizumab (a VEGF-targeted mAb) with sunitinib monotherapy (NCT 
01984242). The number of ongoing and planned trials looking at ipilimumab, nivolumab 
or other PD-1/PD-L1 targeted agents in RCC patients is too large to list them all here. 
Suffice it to say, there is great interest in the observed efficacy to date and possible 
combinations that might yield an increased benefit. 
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CTLA-4 and the PD-1-PD-L1 axis are not the only immune checkpoints with therapeutic 
potential. Exploring blockade of other checkpoint molecules using the Renca orthotopic 
model, either alone or in combination would certainly be worthwhile. Pre-clinical work has 
shown co-expression of lymphocyte activating gene 3 (LAG3) and PD-1 on tumor-
infiltrating CD4s and CD8s. In three transplantable murine models, dual blockade cleared 
tumors that were largely resistant to either monotherapy (68). Mice receiving the 
combination also had increased percentages of IFNγ+ CD8 T cells in their TDLN and TIL. 
Similar results were seen with combining PD-1 and T-cell immunoglobulin and mucin 
domain-3 (TIM-3) antibody blockade in murine tumor models (69). While either antibody 
alone did show some improvement in IFNγ+ CD8 T cell populations, neither resulted in 
complete regression and the anti-tumor effect was limited and variable. The combined 
blockade resulted not only in more robust IFNγ production by CD8 T cells but also a more 
consistent anti-tumor response with 50% of mice achieving complete and lasting regression. 
Though the study did not look at a murine RCC model, it would be reasonable to expect 
similar results. 
While the combination of sunitinib and anti-PD-1 antibody was not effective in our 
orthotopic Renca model or well tolerated in clinical trials, the rationale behind combining 
anti-angiogenic therapy, particularly TKIs, with immune checkpoint blockade is supported 
by an extensive body of literature and should continue to be explored (70). Efforts to 
identify biomarkers associated with response and resistance to both targeted therapies and 
immunotherapies could help to advance the potential of such combinations (17,71,72). The 
promise of a cure lies in combination therapies targeted to an individual’s tumor, not a 
handful of single agents used sequentially for all patients in a particular disease group. 
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With so many exciting developments in both types of treatment, one hopes we will soon 
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